{"id":"amg-386-and-trastuzumab","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Headache"},{"rate":"5-15%","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting Ang-2, AMG 386 reduces the formation of new blood vessels that tumors need to grow. Trastuzumab binds to the HER2/neu receptor on cancer cells, marking them for destruction by the immune system. This dual mechanism of action may help to slow or stop the growth of certain types of cancer.","oneSentence":"AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing it from interacting with its receptor, thereby inhibiting angiogenesis. Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, which is overexpressed in certain cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:46.765Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic breast cancer with HER2 overexpression"},{"name":"Locally advanced or metastatic gastric cancer with HER2 overexpression"}]},"trialDetails":[{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT00807859","phase":"PHASE1","title":"Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-03-09","conditions":"Breast Cancer, Breast Neoplasms, Breast Tumors","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AMG 386 (Trebananib); Trastuzumab (Herceptin)"],"phase":"phase_2","status":"active","brandName":"AMG 386 and Trastuzumab","genericName":"AMG 386 and Trastuzumab","companyName":"QuantumLeap Healthcare Collaborative","companyId":"quantumleap-healthcare-collaborative","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing it from interacting with its receptor, thereby inhibiting angiogenesis. Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, which is overexpressed in certain cancer cells. Used for Locally advanced or metastatic breast cancer with HER2 overexpression, Locally advanced or metastatic gastric cancer with HER2 overexpression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}